Effects of aminoguanidine on adhesion molecule expression of human endothelial cells

Pharmacology

Volumn 55, Issue 3, 1997, Pages 126-135

  Menzel, E J ^a   Neumiiller, J ^b   Sengoelge, G ^a   Reihsner, R ^b,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Adhesion molecules; Advanced glycation end products; Aminoguanidine; Human endothelial cells; Nonenzymatic glycation

Indexed keywords

AMINOGUANIDINE; CD31 ANTIGEN; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UMBILICAL VEIN;

EID: 1842290373     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139520     Document Type: Article

References (36)

1. Cybulski M, Gimbrone M: Endothelial expression of mononuclear leukocyte adhesion molecule during atherogcncsis. Science 1991:251: 788-791.
2. Brownlee M. Ccrami A. Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988:318:1315-1320.
3. Nakamura Y. Horii Y. Nishino T. Shiiki H. Sakaguchi Y. Kagoshima T. Dohi K. Makita Z. Vlassara H. Bucala R: Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes melli-tus. Am J Pathol 1993; 143:1649-1656.
4. Palinski W. Koschinski T. Butler SW. Miller E. Vlassara H. Cerami A. Witztum JL: Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycentic rabbits. Arteriosclcr Thromb Vase Biol 1995:15:571-582.
5. Bucala R. Makita Z. Vega G, Grundy S. Koschinski T. Cerami A, Vlassara H: Modification of low-density lipoprotein by advanced glycation end products contributes to I he dys-lipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;9:9441-9445.
6. Khan B. Parthasarathy S. Alexander RW. Medford RM: Modified low density lipoprotein and its constituents augment cvtokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995; 95:1262-1270.
7. Esposito C, Stern D. Gerlach H, Vlassara H: Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989:170: 1387-1407.
8. Kirstein M, Brett J. Radoff S. Stem D. Vlassara H: Advanced glycosylation end products selectively induce monocyte migration across intact endothelial cell monolayers, and elaboration of growth factors: Role in aging and diabetic vasculopathy. Proc Natl Acad Sci USA 1990;87: 9010-9014.
9. Farkas J. Mcnzcl EJ: Proteins lose their nitric oxide stabilizing function after advanced glycosylation. Biochim Biophys Acta 1995:1245: 305-310.
10. Yan SD, Schmidt AM. Anderson GM. Zhang J. Brett J. Zou YS, Pin-ski D. Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their rcceptors/binding proteins, J Biol Chem 1994:269:9889-9897.
11. Schmidt AM. Mori O. Chen X. Li JF. Crandall G, Zhang J. Cao R. Yan SD. Brett J. Stern D: Advanced glycation end products interacting with their endothelial receptor increase expression of vascular cell adhesion molecule I in cultured human endothelial cells and in mice. J Clin Invest 1995:96:1395-1401.
12. Vlassara H, Full H. Donnely T, Cy-bulski M: Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atherome formation in normal rabbits. Mol Med 1995:1:447-456.
13. Fu MX. Wclls-Knecht KJ. Black-ledge JA, Lyons TJ. Thorpe SR. Baynes JW: Glycation. glycoxida-tion. and cross-linking of collagen by glucose. Kinetics, mechanism, and inhibition of late stages of the Mail-lard reaction. Diabetes 1994;43: 676-683.
14. Brownlee M. Vlassara H. Kooney A. Ulrich P, Cerami A: Aminoguanid-ine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-1632.
15. Brownlee M: Pharmacological modulation of the advanced glycosylation reaction. Prog Clin Biol Res 1989:304:235-248.
16. Menzel EJ, Rcihsner R: Alterations of biochemical and biomechanical properties of rat tail tendons caused by non-cnzvmatic glycation and their inhibition by dibasic amino acids arginine and lysine. Diabcto-logia 1991:34:12-16
17. Sensi M, Pricci F. Rossi MG, Mora-no S, DiMario U: ZXLvsine effectively decreases the non-enzymatic glycation of proteins in vitro. Clin Chem 1989;35:384-387.
18. Shyadehi AZ. HardingJJ: Investigations of ibuprofen and paracetamol binding to lens proteins to explore their protective role against cataract. Biochcm Pharmacol 1991:42:2077-2084.
19. Raza K. Harding JJ: Noncnzymatic modifications of lens proteins by glucose and fructose: Effect of ibuprofen. Exp Eye Res 1991:52:205-212.
20. Hammcs HP. Brownlee M. Edcl-stein D. Saleck M. Martin S. Fcder-lin K: Aminoguanidinc inhibitis the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabctologia 1994: 37:32-35.
21. Bannai C. Yamazaki M. Matsushina Y. Kunika K. Itakura M. Okuda Y, Yamashita K: Amelioration of dermal lesions in streptozotocin-in-duccd diabetic rats by aminoguanidinc. Diabetes Res 1992:20:87-95.
22. Vlassara H. Fuh H. Makita Z. Krungkrai S. Cerami A. Bccala R: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci USA 1992:89:12043-12047.
23. Corbett JA. Tilton RG, Chang K. Hasan KS, Ido Y. Wang JI. Sweet-land MA. Lancaster JR. Williamson JR. McDaniel MI: Aminoguanidinc. a novel inhibitor of nitric oxide formation. prevents diabetic vascular dysfunction. Diabetes 1992:41:552-556.
24. Tilton RG. Chang K. Ostrow E. Allison W. Williamson JR: Aminoguanidinc reduces increased Iocine-131 albumin permeation of retinal and uveal vessels in streptozotocin induced diabetic rats. Invest Ophthalmol Vis Sci 1990:31:342-348.
25. Tilton RG. Chang K. Hasan KS. Smith SR. Petrash JM, Misko TP. Moore WM. Currie MG. Corbett JA. McDaniel ML. Williamson JR: Prevention of diabetic vascular dysfunctions by guanidines. Diabetes 1993;42:221-232.
26. Chibber R. Molinatti PA. Wong JS, Mirlcs D. Kohner EM: The effect of aminoguanidinc and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes 1994: 43:758-763.
27. Holstad M. Sandler S: Aminoguanidinc, an inhibitor of nitric oxide formation, fails to protect against in-sulitis and hyperglycemia induced by multiple low dose streptozotocin injections in mice. Autoimmunity 1993:15:311-314.
28. Ou P. WolffSP: Aminoguanidinc: A dnig proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Bio-chem Pharmacol 1993:46:1139-1144.
29. Schmidt RE. Dorsey DA. Beaudet I.N. Reiser KM, Williamson JR. Tilton RG: Effect of aminoguanidinc on the frequency of neuroaxonal dystrophy in the superior mesenterie sympathetic autonomic ganglia of rats with strcptozotocin-induccd diabetes. Diabetes 1996:45:284-289.
30. Menzel EJ. Reihsncr R: Comparison of the effect of different inhibitors on the non-enzymatic glycation of rat tail tendons and bovine serum albumin. Ann Clin Biochem 1995: 33:1-8.
31. Reihsncr R, Menzel EJ: The influence of L-arginincon biomechanical parameters of native and nonen-zymatically glycated rat tail tendons. Connect Tiss Res 1994:31:55-65.
32. Marui N. Offcrmann MK. Swcrlick R. Kunsch C. Rosen CA. Ahmad M. Alexander RW. Medford RM: Vascular cell adhesion molecule-1 gene transcription and expression arc regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92:1866-1874.
33. Edelstein D. Brownlee M: Mechanistic studies of advanced glycosylation end products inhibition by ami-noguanidine. Diabetes 1992:41:26-29.
34. Picard S. Parthasarathy S. Fruebis J, Witztum JL: Aminoguanidinc inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage receptors. Proc Natl Acad Sci USA 1992:89:6876-6880.
35. Bucala R. Makita Z, Koschinsky T. Cerami A. Vlassara H: Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993:90:6434-6438.
36. Kapiotis S. Sengoelgc G. Spcrr WR. Baghestanian M. Quehenberger P, Bevec D, Li SR, Menzel EJ. Miihl A. Zapolska D. Virgolini I, Valent P. Speiser W: Ibuprofen inhibits pvrogen-dependent expression of VCAM-1 and 1CAM-I on human endothelial cells. Life Sci 1996:58: 2167-2181.